RXi Pharmaceuticals Corporation (RXII)


NasdaqCM - NasdaqCM Real Time Price. Currency in USD
2.400.00 (0.00%)
At close: 4:00 PM EDT
People also watch:
GALECYTROPXACYCCRNN
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Open2.40
Prev Close2.40
Bid0.00 x
Ask14.37 x 2200
Day's Range2.39 - 2.47
52wk Range1.26 - 6.49
1y Target EstN/A
Market Cap15.74M
P/E Ratio (ttm)-1.64
Beta1.24
Volume47,127
Avg Vol (3m)64,750
Dividend & YieldN/A (N/A)
Earnings DateN/A
Trade prices are not sourced from all markets
  • PR Newswire14 days ago

    RXi Pharmaceuticals Reports Second Quarter 2016 Financial Results and Highlights Recent Corporate Developments

    MARLBOROUGH, Mass., Aug. 11, 2016 /PRNewswire/ -- RXi Pharmaceuticals Corporation (NASDAQ: RXII), a clinical-stage RNAi company developing innovative therapeutics that address significant unmet medical ...

  • PR Newswire28 days ago

    RXi Pharmaceuticals to Webcast Second Quarter 2016 Financial Results on Thursday, August 11, 2016

    MARLBOROUGH, Mass., July 28, 2016 /PRNewswire/ -- RXi Pharmaceuticals Corporation (RXII), a clinical-stage RNAi company developing innovative therapeutics that address significant unmet medical needs, today announced that it will report its financial results for the second quarter ended June 30, 2016, and provide a business update on Thursday, August 11, 2016 after the close of the U.S. financial markets. The webcast link is available under the "Investors - Event Calendar" section of the Company's website, www.rxipharma.com.  The event may also be accessed by dialing toll-free in the United States and Canada: +1 888-669-0684. RXi Pharmaceuticals Corporation (RXII) is a clinical-stage RNAi company developing innovative therapeutics that address significant high-unmet medical needs.  Building on the pioneering work of RXi's Scientific Advisory Board Chairman and Nobel Laureate Dr. Craig Mello, our discovery and clinical development programs are based on our proprietary RNAi (sd-rxRNA®) platform and Samcyprone™, a topical immunomodulator.

  • PR Newswirelast month

    RXi Pharmaceuticals to Present at the 2016 Summer Meeting of the American Academy of Dermatology

    On Friday, July 29, 2016, at 2:40 p.m. EDT, during the Infection-Viral Poster Session, Dr. Karen Bulock, RXi's Vice President of Research will give an oral presentation entitled, "Diphenylcyclopropenone Ointment for the Treatment of Common Warts". The American Academy of Dermatology was founded in 1938.